Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

International Journal of Antimicrobial Agents

Volumn 35, Issue 6, 2010, Pages 524-526

  Amaral, Leonard ^a   Boeree, Martin J ^b   Gillespie, Stephen H ^c   Udwadia, Zarir F ^d   van Soolingen, Dick ^e  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d P D HINDUJA NATIONAL HOSPITAL   (India)

^e NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Extensively drug resistant TB; Multidrug resistant TB; Pulmonary tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIORIDAZINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; APPETITE; ARGENTINA; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMPASSIONATE USE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEVER; HUMAN; IN VITRO STUDY; INDIA; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; PRIORITY JOURNAL; RADIODIAGNOSIS; SHORT SURVEY; TERMINAL DISEASE; TUBERCULOSIS; WEIGHT GAIN;

ANIMALS; ANTITUBERCULAR AGENTS; ARGENTINA; CLINICAL TRIALS AS TOPIC; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; INDIA; MICE; MYCOBACTERIUM TUBERCULOSIS; THIORIDAZINE;

EID: 77950849122     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.12.019     Document Type: Short Survey

References (15)

1. Faustini A., Hall A.J., Perucci C.A. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006, 61:158-163.
2. Frieden T.R., Sterling T., Pablos-Mendez A., Kilburn J.O., Cauthen G.M., Dooley S.W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993, 328:521-526.
3. Munsiff S.S., Bassoff T., Nivin B., Li J., Sharma A., Bifani P., et al. Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997. Emerg Infect Dis 2002, 8:1230-1238.
4. World Health Organization. Anti-tuberculosis drug resistance in the world. Report No. 4. Geneva, Switzerland: WHO; 2008.
5. Perdigão J., Macedo R., João I., Fernandes E., Brum L., Portugal I. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 2008, 14:133-143.
6. Velayati A.A., Masjedi M.R., Farnia P., Tabarsi P., Ghanavei J., Ziazarifi A.H., et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
7. Amaral L., Kristiansen J.E., Abebe L.S., Millet W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for the initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996, 38:1049-1053.
8. Ordway D., Viveiros M., Leandro C., Amaral L. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:917-922.
9. Martins M., Viveiros M., Amaral L., Couto I., Molnar J., Boeree M., et al. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB). Int J Antimicrob Agents 2008, 33:479-482.
10. Martins M., Viveiros M. Amaral l. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 2007, 21:771-776.
11. Abbate E., Vescoso M., Natiello M., Cufre M., Garcia A., Ambroggi M., et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Revista Argentina de Medicina Respiratoria 2007, 1:19-25.
12. Thanacoody H.K.R. Thioridazine: resurrection as an antimicrobial agent?. Br J Clin Pharmacol 2007, 64:566-574.
13. Udwadia Z.F. India's multidrug-resistant tuberculosis crisis. Ann N Y Acad Sci 2001, 953:98-105.
14. Mitnick C.D., Castro K.G., Harrington M., Sacks L.V., Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med 2007, 4:e292.
15. Mitchison D.A. Clinical development of anti-tuberculosis drugs. J Antimicrob Chemother 2006, 58:494-495.